T he last two decades have witnessed a remarkable progress in mechanical circulatory support systems for patients with advanced heart failure (HF), resulting in improved functional capacity, quality of life, and survival in this population [1] [2] [3] . Recent advances in device technology led to the development of continuous-flow pumps, which have become standard of care for HF patients both as a bridge to transplantation (BTT) and destination therapy [4] [5] [6] . The HeartMate II left ventricular assist device (HMII-VAD; Thoratec Corp, Pleasanton, CA) is among the most widely used support systems worldwide, and remains the only continuous-flow device currently approved for both BTT and destination therapy indications in the United States. Although outcomes have significantly improved with this pump, HMII-VAD implantation is still associated with early and late device-related complications including infections, gastrointestinal bleeding, and thrombotic events [7] [8] [9] .
More recently, the HeartWare (HeartWare Inc, Framingham, MA) ventricular assist device (HW-VAD), a third-generation continuous-flow pump, was introduced into clinical use [10, 11] . The HW-VAD is a miniaturized centrifugal flow pump that is directly implanted into the failing left ventricle and situated in the intrapericardial space, eliminating the need for the abdominal incision that is routinely performed in HMII-VAD implantation [10] . Recently published ADVANCE trial demonstrated noninferior postimplantation outcomes in patients undergoing HW-VAD implantation compared with a contemporary control group from the INTERMACS registry, leading to the approval of this device by the US Food and Drug Administration for BTT [12] . However, no study to date has directly compared posttransplant outcomes of patients bridged with HW-VAD or HMII-VAD support. Moreover, data regarding differences in hemodynamic unloading patterns, end-organ function, and antigen sensitization levels between the recipients of these two left ventricular assist device (LVAD) types are either limited or lacking. In an effort to address these questions, we performed a comparative analysis of patients bridged to transplantation with HW-VAD or HMII-VAD using the multicenter United Network for Organ Sharing (UNOS) database, given the relatively small number of HW-VAD implants at any individual center.
Material and Methods

Data Collection
Standard analysis and research files were obtained from UNOS in October 2012, which included data from all heart transplant recipients and donors in the United States reported to the Organ Procurement and Transplantation Network between October 1, 1987, and July 31, 2012. Given the deidentified nature of the data set, exemption status was granted by the institutional review board at our center.
Study Population
The study included patients aged 18 and older who underwent cardiac transplantation between January 1, 2009, and July 31, 2012. Patients who underwent previous heart transplantation or simultaneous transplantation were excluded from the analysis. The LVAD type was identified using LVAD data points represented in the standard UNOS transplant recipient registration forms. Patients who were transplanted after either HW-VAD or HMII-VAD implantation were included in the final analysis. Mean posttransplant follow-up time for the data set was 439 days.
Examined Variables and Outcome Measures
The UNOS transplant data registry contains more than 400 pretransplant and postoperative data points. Recipient baseline characteristics examined were age, sex, ethnicity, height, weight, body mass index, HF etiology, presence of diabetes, serum creatinine and total bilirubin, panel reactive antibodies, and ABO mismatch level. Body surface area was calculated using the Mosteller formula. Pretransplant hemodynamic values examined were cardiac output, cardiac index, pulmonary artery pressures (systolic, diastolic, and mean), pulmonary capillary wedge pressure, transpulmonary gradient, and pulmonary vascular resistance. Donor baseline characteristics examined were age, sex, ethnicity, height, weight, body mass index, presence of diabetes, serum creatinine, total bilirubin, and ischemic time.
Early clinical outcomes analyzed were need for dialysis, pacemaker implantation, and stroke before discharge. Hospital lengths of stay and 30-day mortality rates were also calculated for each group. Long-term outcome variables examined were posttransplant graft survival, freedom from cardiac allograft vasculopathy (CAV), and freedom from hospitalization for allograft rejection.
Statistical Analysis
Continuous data was reported as mean and standard deviation, and was compared using independent student ttests. Categorical variables were represented as percentages and compared using chi-squared or Fisher's exact tests where appropriate. Kaplan-Meier survival analysis was performed to compare graft survival, freedom from CAV, and freedom from hospitalization for rejection. Logrank tests were utilized when comparing groups.
Propensity scores were created for comparing HeartMate II and HeartWare LVADs as BTT devices. Recipient and donor baseline variables were used to create score, except for peak class I and class II PRA percentages, which were omitted due to missing data. A Greedy matching algorithm was used to match HeartWare and HeartMate II. Standardized differences were computed before and after matching to evaluate covariate balance. For patient survival and the outcomes rejection and CAV, Cox proportional hazards models were created and the hazard ratio was used to compare groups before and after matching. For the matched analysis, a shared frailty modeling technique was used. For the binary outcomes of posttransplant dialysis, pacemaker implantation, posttransplant stroke, and 30-day mortality, logistic regression models were built. The odds ratio was used to compare the HW-VAD with the HMII-VAD. A linear regression model was built for length of stay, and the beta coefficient was used to estimate the difference between groups. The logistic and linear regression models were created using Generalized Estimating Equations methods to account for matching.
All tests were conducted at the alpha ¼ 0.05 level. All analyses were conducted in SAS v9.3 (SAS Institute, Inc, Cary, NC).
Results
Study Population
The study population was composed of 1,965 heart transplant recipients: 141 (7.2%) bridged with HW-VAD and 1,824 (92.8%) bridged with HMII-VAD from 2009 through July 2012 ( Fig 1A) . The number of patients bridged with HW-VAD and HMII-VAD steadily increased during the study period, consistent with increased use of mechanical circulatory support systems in the advanced HF population. The percentage of patients bridged with HW-VAD increased from 4.3% in 2009 to 9.5% in 2012 (Fig 1B) .
Baseline Characteristics
Recipient clinical characteristics were well matched between the two device groups (Table 1 ). However, there was a higher proportion of female patients in the HW-VAD group compared with the HMII-VAD group (27.0% versus 18.9%; p ¼ 0.019). Consequently, mean body weight and mean body surface area were also found to be significantly lower in HW-VAD recipients (Table 1 ). In addition, there was a trend toward significance in peak class I panel reactive antibody levels, which were found to be higher in HW-VAD recipients (40.4% versus 33.0%; p ¼ 0.070). However, there were no significant differences between the two groups in the most recent class I or class II panel reactive antibody levels.
Donor clinical characteristics were also well matched between the two groups ( Table 2 ). There were no significant differences in donor age, sex, bilirubin level, and ischemic time. However, donor creatinine level was significantly lower in the HW-VAD group (1.19 versus 1.35; p ¼ 0.045). 
Hemodynamic Profiles
Pretransplant recipient hemodynamic profile data are summarized in Table 3 . Overall, there were no statistically significant differences in cardiac output, cardiac index, pulmonary artery pressures, pulmonary capillary wedge pressure, transpulmonary gradient, or pulmonary vascular resistance between the two groups before cardiac transplantation.
Posttransplant Outcomes
Early posttransplant complications including pacemaker implantation, postoperative dialysis, and postoperative stroke were comparable between the groups (Table 4) . Thirty-day mortality rates and hospital lengths of stay in these patients were also similar. Only a small number of patients (n ¼ 7) required retransplantation during the follow-up period. The data showed no significant difference in posttransplant graft survival between patients who were bridged with HW-VAD and those who were bridged with HMII-VAD. Graft survival rates of HW-VAD recipients at 1, 2, and 3 years were 88.4%, 79.9%, and 77.4% with 87.8%, 83.8%, and 79.9% in HMII-VAD recipients, respectively (p ¼ 0.843; Fig 2) . Freedom from CAV and freedom from hospitalization for rejection were comparable between HW-VAD and HMII-VAD recipients (Fig 3) . Table 5 demonstrates outcome results for propensitymatched HW-VAD and HMII-VAD BTT cohorts (n ¼ 124 patients in each arm). As shown in the table, no significant differences were found between the groups before or after propensity matching with regard to posttransplant patient survival, freedom from rejection, freedom from CAV, posttransplant dialysis, posttransplant pacemaker implantation, posttransplant stroke, early mortality, and hospital length of stay (all p > 0.05).
Propensity-Matching Analysis
Comment
The clinical safety and efficacy of HW-VAD therapy were initially assessed in a number of single-arm prospective studies carried out in European and Australian centers, which demonstrated excellent post-VAD survival and quality of life after HW-VAD support [13, 14] . These findings provided the rationale for the ADVANCE trial, which was a multicenter, prospective study comparing the clinical efficacy of HW-VAD therapy against a contemporaneous control group obtained from the INTERMACS registry. The primary outcome of the ADVANCE trial was defined as survival on the originally implanted device, transplantation, or explantation of the device for ventricular recovery at 180 days. Despite the lack of a true control group, the ADVANCE trial demonstrated noninferiority in the primary outcome in patients who had received HW-VAD compared with a control group [12] . Moreover, HW-VAD therapy was associated with a favorable adverse effect profile, and with improvements in functional capacity and quality of life. Based on these findings, HW-VAD therapy was recently approved by the US Food and Drug Administration for BTT in patients with end-stage HF. The current study extends the findings of the ADVANCE trial and supports the use of HW-VAD as a BTT, and provides valuable insight into outcomes of patients undergoing HW-VAD implantation with regard to their baseline characteristics, hemodynamic profile, and posttransplant outcomes, which were not reported in the ADVANCE trial. Our data suggest that the proportion of women bridged to transplantation was significantly higher in HW-VAD recipients compared with HMII-VAD recipients. Mean body weight and body surface area were also statistically lower in patients bridged with HW-VAD, which could be explained by the higher proportion of women in this group. Although there were no differences in sex distribution between HW-VAD and the control group in the ADVANCE trial, the smaller size of the HeartWare device compared with other commercially available LVADs may allow for implantation of this device in patients with lower body surface areas. Indeed, HW-VAD was successfully implanted in a pediatric population for dilated cardiomyopathy and congenital heart disease, and thus offers an attractive alternative to paracorporeal support systems in this patient group [15, 16] .
The degree of hemodynamic unloading with HeartWare versus HeartMate II device support in patients with advanced HF has been previously investigated in a number of clinical studies. Haft and colleagues [17] reported a 26% increase in mean cardiac index, a 41% decrease in mean pulmonary artery pressure, and a 52% decrease pulmonary capillary wedge pressure after 3 months of device support in 18 patients who underwent HeartMate II implantation. Similarly, McDiarmid and colleagues [18] reported a 35% increase in cardiac index, a 68% decrease in mean pulmonary artery pressure, and a 50% decrease in pulmonary capillary wedge pressure after nearly 1 year of device support in 30 patients who underwent HeartWare implantation. Pauwaa and colleagues [19] comparatively analyzed postimplantation hemodynamics in 15 patients supported with either HeartWare (n ¼ 6) or HeartMate II (n ¼ 9) devices, and did not demonstrate any significant differences between the two support systems. Our analysis in a larger cohort of individuals supported with continuous-flow devices also suggests that the degree of hemodynamic unloading is comparable in HeartWare and HeartMate II recipients. End-organ function on LVAD support is crucial for long-term outcomes and potential candidacy for cardiac transplantation. Early preclinical studies have demonstrated excellent end-organ function in both ovine and bovine models supported by HeartWare devices, up to 90 days after transplantation [20, 21] . In parallel with the preclinical data, early clinical studies have also shown improvements in end-organ function of patients supported by the HeartWare device [13, 14] . Similarly, improvements in renal and hepatic function were evident in patients undergoing HeartMate II implantation for a BTT [4] . Time-dependent changes in renal or liver function after LVAD implantation were not reported in the ADVANCE trial. However, our findings suggest that HeartWare and HeartMate II devices lead to comparable improvements in end-organ function.
The presence of circulating anti-HLA antibodies in cardiac transplant candidates remains a major obstacle for donor selection and may limit the long-term success of heart transplantation owing to increased rates of rejection and posttransplant mortality [22] . Previous studies have shown that patients bridged to transplantation with mechanical circulatory support have a higher prevalence of allosensitization compared with patients who are bridged with medical therapy, and that the prevalence of sensitization in LVAD recipients is correlated with the duration of support [23, 24] . Studies have also demonstrated lower rates of allosensitization in patients who received a HeartMate II continuous-flow device compared with patients who received a HeartMate I pulsatile-flow device [24, 25] . However, the effect of HeartWare device implantation on allosensitization of transplant-eligible patients remains unknown. The current analysis suggests comparable levels of class I and class II panel reactive antibodies in patients supported with HeartWare and HeartMate II LVADs, although we found a trend toward a higher peak class I panel reactive antibody percent in HeartWare recipients. Although this finding could be explained in part by the presence of a higher proportion of female recipients in the HeartWare group, further studies are warranted to investigate the effects of HeartWare implantation on recipient allosensitization. Freedom from allograft rejection and CAV were found to be comparable between HeartWare and HeartMate II recipients, suggesting that the observed difference in peak class I panel reactive antibody levels in the current study did not lead to an increase in clinically significant acute or chronic rejection episodes in HeartWare recipients.
Our study showed no difference in posttransplant graft survival between HW-VAD and HMII-VAD recipients. These findings are consistent with previous analyses from the International Society for Heart and Lung Transplantation and UNOS registries that demonstrated comparable posttransplantation survival in patients bridged with either pulsatile or continuous-flow devices. These observations suggest that the support device type may not have an effect on posttransplant mortality in patients requiring mechanical circulatory support before transplantation [26] [27] [28] .
There were several limitations of the current study. The number of patients bridged to transplantation with the HeartWare device was relatively small compared with patients bridged to transplantation with the HeartMate II during the study period. Important clinical data points, such as post-LVAD outcomes and duration of mechanical support, were not available in the UNOS data set. Moreover, long-term posttransplant complication data were missing for a significant proportion of patients. Given the recent approval of the HeartWare device by the US Food and Drug Administration, the great majority of HeartWare patients analyzed in this study likely represent clinical trial patients, which may introduce selection bias. Although the UNOS reporting system provides consistent definitions, we cannot rule out variations in data entry from center to center.
In conclusion, our study extends the findings of the ADVANCE trial and provides valuable long-term data in patients who received continuous-flow device support as a BTT. Mechanical unloading with the HeartWare device leads to comparable levels of allosensitization, hemodynamic profiles, and end-organ function before transplantation compared with the HeartMate II device. Posttransplantation outcomes including freedom from rejection, CAV, and posttransplant survival are also similar between the two device types. Our findings support use of both the HeartWare and HeartMate II devices in transplant-eligible patients. 
INVITED COMMENTARY
The article from Topkara and colleagues [1] describes a retrospective nonrandomized analysis of 1824 patients with Thoratec HeartMate II (HMII) and 141 patients with HeartWare HVAD implantation. Data were collected from the Organ Procurement and Transplantation network databank. The article has not shown any significant differences in the outcomes after bridging to cardiac transplantation with the applied pump systems. As recently reported, the ADVANCE Trial proved the noninferiority of the HeartWare HVAD pump in a comparison with HMII LVAD in a bridge to cardiac transplant cohort of patients, which implies the clinical justification of this work. Limitations include the higher number of patients in the HM II group and the assumption that a higher proportion of this group of patients was treated for real-life indications, which are less restrictive than clinical trial inclusion criteria under which the HVAD group was enrolled. Additionally, the
